http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9313210-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70528
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
filingDate 1992-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93c7cc375e3f7857323e9bd71d36f311
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a638215984fd41db8b3a32c70640cdfb
publicationDate 1993-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-9313210-A1
titleOfInvention Icams immunoglobulin constant region soluble fusion proteins
abstract Soluble fusion molecules were prepared which contained a CD11a/CD18 specific binding region operatively linked to an immunoglobulin constant region. These molecules particularly include extracellular portions of adhesion molecules such as ICAM-1 and ICAM-2 attached to IgG constant regions. The fusion molecules described are utilized as costimulatory agents for the activation of T cells and in methods for increasing CD4+ T cell proliferative response and IL-2 induction.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0100854-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0100854-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6130202-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7670602-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7229962-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8372961-B2
priorityDate 1991-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0387668-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0365837-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649

Total number of triples: 40.